Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares, rose in value on Friday, June 20, with the stock price down by -1.17% to the previous day’s close as strong demand from buyers drove the stock to $0.25.
Actively observing the price movement in the last trading, the stock closed the session at $0.26. Referring to stock’s 52-week performance, its high was $1.48, and the low was $0.20. On the whole, ADAP has fluctuated by -11.94% over the past month.
With the market capitalization of Adaptimmune Therapeutics Plc ADR currently standing at about $65.24 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ADAP’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ADAP currently trading nearly -6.95% and -5.97% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.49, while the 7-day volatility ratio is showing 2.61% which for the 30-day chart, stands at 3.31%. Furthermore, Adaptimmune Therapeutics Plc ADR (ADAP)’s beta value is 2.25, and its average true range (ATR) is 0.02.
A comparison of Adaptimmune Therapeutics Plc ADR (ADAP) with its peers suggests the former has fared considerably weaker in the market. ADAP showed an intraday change of -1.17% in last session, and over the past year, it shrunk by -73.00%%.
Data on historical trading for Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) indicates that the trading volumes over the past 3 months, they’ve averaged 1.77 million. According to company’s latest data on outstanding shares, there are 257.85 million shares outstanding.
Nearly 11.33% of Adaptimmune Therapeutics Plc ADR’s shares belong to company insiders and institutional investors own 34.07% of the company’s shares. The stock has fallen by -53.04% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ADAP stock heading into the next quarter.
